Newbridge Financial Services Group, Inc. Intellia Therapeutics, Inc. Transaction History

Newbridge Financial Services Group, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 17, 2023	SELL	$31.62 - $45.78 $664 - $961	-21 Closed	0 $0
Q3 2022 Oct 13, 2022	SELL	$53.92 - $71.7 $1,941 - $2,581	-36 Reduced 63.16%	21 $1,000
Q2 2022 Jul 15, 2022	SELL	$38.49 - $76.21 $27,674 - $54,794	-719 Reduced 92.65%	57 $3,000
Q1 2022 Apr 26, 2022	BUY	$58.27 - $118.99 $14,917 - $30,461	256 Added 49.23%	776 $56,000
Q4 2021 Jan 19, 2022	BUY	$100.76 - $138.36 $48,767 - $66,966	484 Added 1344.44%	520 $61,000
Q3 2021 Oct 27, 2021	SELL	$132.37 - $176.78 $3,176 - $4,242	-24 Reduced 40.0%	36 $5,000
Q1 2021 Sep 07, 2021	BUY	$46.59 - $83.68 $2,795 - $5,020	60 New	60 $5,000
Q4 2020 Sep 07, 2021	SELL	$18.83 - $63.53 $0 - $0	0 Closed	0 $0
Q3 2020 Sep 07, 2021	BUY	$17.47 - $24.93 $0 - $0	0 New	0 $0

312

91.4M

417K

824K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.15B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.